Lenalidomide improves PFS after 1st and 2nd line CLL therapyDecember 14, 2016Leukemia, Myelodysplasia, Transplantation
Good response from CAR T cells with ‘safety switch’ for advanced ALLDecember 13, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: Novel, multi-arm trial aims to beat AMLDecember 5, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: Addition of antibody drug conjugate produces deep AML remissionsDecember 5, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: Combination venetoclax-LDAC therapy boosts overall survival in AMLDecember 4, 2016Leukemia, Myelodysplasia, TransplantationPractice Management
VIDEO: CPX-351 may allow more high-risk AML patients to have allogeneic transplantsDecember 4, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: Half-dose TKI safe, cost-effective in CML in stable remissionDecember 4, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: 33A + ‘7 + 3’ equals good remission numbers in untreated AMLDecember 4, 2016Leukemia, Myelodysplasia, Transplantation
Halving the TKI dose safe, cost effective in CML patients with stable remissionsDecember 4, 2016Leukemia, Myelodysplasia, Transplantation
Anti-CD22 CAR T-cells shift ALL into complete remissionDecember 4, 2016Leukemia, Myelodysplasia, Transplantation
VIDEO: Anti-CD22 CAR for R/R ALL impresses in early trialDecember 3, 2016Leukemia, Myelodysplasia, Transplantation
Decitabine elicits favorable response in high-risk AML/MDSNovember 23, 2016Leukemia, Myelodysplasia, Transplantation
Idelalisib held unlikely to become frontline therapy for CLLNovember 23, 2016Leukemia, Myelodysplasia, Transplantation
